Notice for another Special Window for Transfer of Physical Shares –
SEBI vide its circular no. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated 30 January 2026 has decided to open another special window for a period of one year from 05 February 2026 to 04 February 2027, for transfer of physical shares, which were sold/purchased prior to 01 April 2019, including such transfer requests which were submitted earlier and were rejected or returned or not attended to due to deficiency in the documents/ process/or otherwise, in order to facilitate ease of investing for investors and to secure the rights of investors in the securities which were purchased by them. During this period, the securities so transferred shall be mandatorily credited to the transferee only in demat mode and shall be under lock-in for a period of one year from the date of registration of transfer. Such securities shall not be transferred/lien-marked/ pledged during the said lock-in period.
The concerned investors are requested to take advantage of this Special Window, which remains open until 04 February 2027, to submit the documents such as; (a) Original share certificate(s), (b) Transfer deed executed prior to 01 April 2019, (c) Proof of purchase by Transferee, as may be available, (d) KYC documents of the transferee (as per ISR forms), (e) Latest Client Master List (CML), not older than 2 months, of the demat account of the transferee, duly attested by Depository Participant, (f) Undertaking cum Indemnity, to the Company’s Registrar and Share Transfer Agent (RTA) at RCMC Share Registry Pvt Ltd, B-25/1, 1st Floor, Okhla Industrial Area, Phase-II, New Delhi-110020, India.
UPDATE KYC AND CONVERT PHYSICAL SHARES INTO DEMAT MODE
The Shareholders who are holding shares in Physical form are requested to update their KYC and also requested to convert their physical share Certificates in to dematerialized form (electronic Form). Further pursuant to SEBI Circular No. SEBI/Cir/ISD/3/2011 dated June 17, 2011 in order to promote dematerialization of securities, it is mandatory for the Company to achieve 100% of promoter’s and promoter group’s shareholding in dematerialized form, thereby they are requested to convert their holdings in dematerialized form on priority basis.
URGENT FOR SHAREHOLDERS –
In terms of SEBI Circular SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2023/37 dated March 16, 2023, it hereby informed to all holders of physical securities of Brawn Biotech Limited to furnish their PAN, Nomination, Contact details (Email id and Mobile No.), Bank A/c Details and Specimen Signatures for their corresponding folio numbers.
IMPORTANT: In the event of non-receipt of the above details, concerned shares shall be frozen from October 01, 2023
URGENT FOR PROMOTER AND PROMOTERS’ GROUP-
UPDATE KYC AND CONVERT PHYSICAL SHARES INTO DEMAT MODE
The Shareholders who are holding shares in Physical form are requested to update their KYC and also requested to convert their physical share Certificates in to dematerialized form ( electronic Form).Further pursuant to SEBI Circular No. SEBI/Cir/ISD/3/2011 dated June 17, 2011 in order to promote dematerialization of securities, it is mandatory for the Company to achieve 100% of promoter’s and promoter group’s shareholding in dematerialized form, thereby they are requested to convert their holdings in dematerialized form on priority basis.
We Distribute Health Care Products in Domestic and International Markets
Brawn Biotech
BRAWN, with its inception barely 39 years back(1986) has today evolved into a fully integrated, healthcare group, marking its presence in India and dotting various major markets across the globe. BRAWN is proud to possess product registration with major health and govt. institutions throughout India and in many other countries worldwide. Headed and represented by a team of skilled industry experts with impressive educational backgrounds and broad experience, BRAWN continues to spread its wings in expansion in the domestic as well as in the international markets with a vision beyond the existing horizon to stand among the leading Indian HealthCare product distribution Companies.
Investors
Investors can email their queries to solution@brawnbiotech.com
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.




